Dragon Jade International Limited
Dragon Jade International — Investor Presentation (April 2019)
33 slides from Dragon Jade International's investor presentation, Apr 30, 2019
Slide 1: Dragon Jade International Limited Investor Presentation April 2019
Dragon Jade International Limited. (OTC QX: DGJI) Investor Presentation April 2019
Slide 2: Forward Looking Statement
Forward Looking Statement 2 This presentation contains forward - looking statements that reflect our current expectations and views of future events . You can identify some of these forward - looking statements by words or phrases such as "may," "will," "should," "expect," "anticipate," "aim," "esti
Slide 3: Contents
01 02 03 04 • Company Summary Company Summary, Investment Highlights • Company Overview Company Overview, Business Model, Market Coverage • Hemorrhoids Treatment Industry Overview, Hemorrhoids Hydrolysis Technology • Cross - border Healthcare Industry Overview, KPM, Customer Sourcing Strategy, Reven
Slide 4: Company Summary
Company Summary Company Dragon Jade International Limited. Exchange & Ticker Symbol OTC QX 㸸 DGJI Shares Outstanding 57,023,319 Ordinary Shares * F inancial A dvisor Univest Securities, LLC. Legal Counsel Ortoli Rosenstadt LLP Auditor Centurizon ZD CPA Limited 4 This is not an offer to sell or buy s
Slide 5: Investment Highlights
Investment Highlights Expertise • In - depth knowledge of operating and regulatory regimes across distinct regions Experience • Over 20 - year experienced management team with medical background Demand • Considerable growth of demand for cross - border healthcare in China, particularly due to the in
Slide 6: Business Model
Business Model See Registration Statement for full disclosures and risks. Source F - 1 P4 Corporate Information High Net Worth Mainland Patients Hong Kong Healthcare Networks 5 - Star Hotels and Private Clubs Airlines, Insurance, and Others High Net Worth Data Exchange Between Clients Mainland Healt
Slide 7: Company Overview
Company Overview • Headquarter: Hong Kong • More than 20 years of experience and expertise in medical industry • Broad network with local doctors, high - end hospitals, and clinics in Hong Kong • Exclusive hemorrhoids treatment technology owner and provider • C ross - border healthcare service provi
Slide 8: Potential Market Coverage
Potential Market Coverage Our business network covers all over the world: Europe, America, Hong Kong, Macau, Mainland China, Taiwan, Singapore, Malaysia, Thailand, etc. 8 See Registration Statement for full disclosures and risks. * Source: F - 1 Page2
Slide 9: Business Line — Hemorrhoids Treatment
Montrose Fine Wines Dragon Jade International Limited Cross - border Healthcare KPM Professional Doctors Advanced Medical Equipment Latest Treatment Private Health Insurance Complete Supervision System Hemorrhoids Hemorrhoids Hydrolysis Technology Machine Provider Kit Provider (1) Business Line — H
Slide 10: About Hemorrhoids
About Hemorrhoids Hemorrhoids are swollen veins in the lower part of the anus and rectum. When the walls of these vessels are stretched, they become irritated. What are Hemorrhoids Causes of Hemorrhoids Common Patients • Unhealthy eating habits / Low fiber Diet • Prolong sitting / Standing / Squatin
Slide 11: Hemorrhoid Treatment Stage Comparison
Hemorrhoid Treatment Stage Comparison Stage 1 Stage 2 Stage 3 Stage 4 A first - grade internal hemorrhoid bulges into the anal canal during bowel movements. A second - grade internal hemorrhoid bulges from the anus during bowel movements, then goes back inside by itself . A third - grade hemorrhoid
Slide 12: Hemorrhoid Treatment – Market Size
Hemorrhoid Treatment – Market Size Note ： *Market Size Calculation Formula ： The total number of Hemorrhoids patients seeking for treatment in China * Treatment cost (6,500 RMB) Source 㸸 1. Results of National Epidemiological Anorectal Disease Survey 2. Statistical Communiqué of the People’s Republi
Slide 13: Hemorrhoids Hydrolysis Technology
Hemorrhoids Hydrolysis Technology Place probe at the base of the hemorrhoid Alkaline Environment H2 A registered Western doctor will first conduct a preliminary examination using a special anoscope, to understand the situation and confirm the position of hemorrhoids Special Anoscope Internal Hemorrh
Slide 14: Treatment for Hemorrhoids
Treatment for Hemorrhoids 14 Hemorrhoids Hydrolysis Technology Traditional Surgery Rubber Band Ligation PPH Surgery Ointment/Medical towel/Medical cushion treatment Radical Cure Low Pain Protects Rectal Structure Non - Traumatic /RZ5HFXUUHQFH 5DWH Suitable for all - stage treatment No Hospitalizat
Slide 15: Hemorrhoids Hydrolysis Technology – Competitive Advantages
Hemorrhoids Hydrolysis Technology – Competitive Advantages Non - invasive Clinical treatment by a general practitioner (GP) Multiple clinical trials proof of efficacy No need for hospitalization or anesthesia Suitable for treatment of hemorrhoids at all stages 15 The best choice for patients with re
Slide 16: Hemorrhoids Hydrolysis Technology Project Timeline
Hemorrhoids Hydrolysis Technology Project Timeline 16 2018.5 2019.12 Complete CFDA Class 2 Medical Device Certification & Trademark Registration Expected to obtain approval from CFDA See Registration Statement for full disclosures and risks.
Slide 17: Business Line — Cross-Border Healthcare
Montrose Fine Wines Dragon Jade International Limited Cross - border Healthcare KPM Professional Doctors Advanced Medical Equipment Latest Treatment Private Health Insurance Complete Supervision System Hemorrhoids Hemorrhoids Hydrolysis Technology Machine Provider Kit Provider (2)Business Line — Cro
Slide 18: Cross-border Healthcare – Industry Overview
Cross - border Healthcare – Industry Overview 39.7% Percentage of Chinese patients seeking cross - border treatment for incurable diseases 1 Chinese cross - border healthcare tourism market in 2016 2 (RMB) Average annual growth rate of global cross - border healthcare market 3 Estimated population s
Slide 19: Cross-Border Healthcare – Competitive Advantages
Private Health Insurance: Hong Kong‘s commercial health insurance penetrate most of the population, and there is a huge amount of people from mainland China come to Hong Kong for purchasing commercial health insurance. Cross - Border Healthcare – Competitive Advantages Hong Kong has been the best ch
Slide 20: KPM Healthcare Centre (Under MOU to Acquire)
KPM Healthcare Centre (Under MOU to Acquire) 20 See Registration Statement for full disclosures and risks. 6 Beds of ICU Medical Beauty Day Surgery MRI, 640 - Slices CT - Scan, Endoscope, Ultrasound, PET - CT Scan Four Core Services
Slide 21: KPM Healthcare Centre
KPM Healthcare Centre Bridge the latest treatments and therapies between the west and east. KPM is the only private full - service medical center equipped with a suite of advanced medical equipment in Hong Kong . KPM is the only private medical center in Hong Kong that conducts medical radiological
Slide 22: Database & Resources of HNW Clients
Database & Resources of HNW Clients Database acquired through the acquisition of Hong Kong Montrose Fine Wines 22 Hotels Private Clubs 60 millions people from Mainland travel to Hong Kong each year Montrose Fine Wines that we acquired helped obtain large number of both existing and potential cross -
Slide 23: Customer Sourcing Strategy
Customer Sourcing Strategy 23 DGJI’s Big Data Center Develop HNW customer group Cross strategy for well - known corporate customer groups Cooperation with medical companies around the world Digital marketing on social media Acquire HNW customers by acquisition of companies Cooperation with life and
Slide 24: Cross-border Healthcare Strategic Partners
Cross - border Healthcare Strategic P artners 24 Apparel Insurance Airlines Data Exchange Between Clients See Registration Statement for full disclosures and risks.
Slide 25: Revenue Growth Drivers
Revenue Growth Drivers Increasing Awareness of Cross - Border Healthcare 1 The Consumption Levels of Middle - Class Continue to Increase 4 A Huge Potential Market to be Explored 3 Solid Growth of Customer Groups 2 • Approximately 40% of the high - income population in China acknowledged the benefits
Slide 26: Financial Forecast
F in ancial Forecast $29.04 $41.93 $58.11 $78.30 $ - $20.00 $40.00 $60.00 $80.00 $100.00 2020 2021 2022 2023 Cross - Border Segment Revenue Million Million $632.47 $929.74 $1,255.15 $1,903.64 $- $400.00 $800.00 $1,200.00 $1,600.00 $2,000.00 2020 2021 2022 2022 Hemorrhoids Treatment Revenue 26
Slide 27: Financial Forecast – Hemorrhoids Treatment Segment
F in ancial Forecast USD 2020 2021 2022 2023 Segment - Hemorrhoids Treatment Driver one: Sales of Devices 2,302,000$ 3,383,940$ 4,568,319$ 6,928,617$ Total Number of Grade III Hopitals in China 1,151 1,151 1,151 1,151 Grade III Hospital Occupancy Rate 25% 35% 45% 65% Number of Cooperated Grade III H
Slide 28: Management Team & Board of Directors
Management Team & Board of Directors Mr . Law Lok Bun , age 67 , is an Executive Director and the President of the Company . He was appointed as an Executive Director of the Company on April 17 , 2012 . He is responsible for planning the overall direction of the Company and managing the Company’s da
Slide 29: Independent Director
Independent Director Mr . Lo Tsz Fung Philip , age 53 , was appointed as an Independent Non - executive Director of the Company on September 1 , 2012 . Mr . Lo was appointed as a director and the Chairman of the Audit Committee and a member of the Compensation Committee and Corporate Governance Comm
Slide 30: Independent Director
Independent Director Dr . Dominic Man - Kit Lam , age 72 , was appointed as an Independent Director of the Company on January 25 , 2019 . Dr . Lam has over 40 years of experience in biotechnology development, research, and education . He is currently Chief Scientific Consultant at Chaoda Modern Agri
Slide 31: Independent Director
Independent Director Ms . Suk - Kwan Kwong was appointed as an Independent Director of the Company on January 25 , 2019 . She has been a registered nurse and holds a nursing practicing certificate issued by the Nursing Council of Hong Kong since 2000 . Ms . Suk - Kwan Kwong currently serves as a hea
Slide 32: Board Committee
Board Committee 32 Mr. David P. Bennett has joined as a member of the audit committee and the chairman of the nominating committee of the Board. Ms. Suk - Kwan Kwong has joined the Board as the chair of the compensation committee and a member of the nominating committee. Mr. Marc - Andre Tremblay ha
Slide 33: Contact Information
Contact Information Sam Tu Vice President Email: sam@dgjigroup.com Tel: (852) - 9490 - 8800 Address: Unit 07, 3/F, Yale Industrial Ctr , 61 - 63 Au Pui Wan St, Fotan , N.T., Hong Kong 33 Edric Guo COO Email: yguo@univest.us Tel: ( 646 ) - 775 - 0000 Address: 375 Park Avenue 15th Floor New York, NY 1
Dragon Jade International — Investor Presentation (April 2019) on 6ix